INTRODUCTION
Oxaliplatin remains one of the lead treatments for colorectal cancers. 1 However, its anticancer efficacy is associated with adverse drug reactions and particularly chemotherapy-induced peripheral neuropathy (CIPN), which is the main dose-limiting toxicity 2 of this treatment. Chronologically, oxaliplatin induces acute and transient nerve hyperexcitability followed by a chronic cumulative peripheral neuropathy. 3 Oxaliplatin is certainly one of the most neurotoxic anticancer drugs, alongside Vinca alkaloids, taxanes, bortezomib and thalidomide. 3 More than 90% of patients experience acute symptoms which are however resolved within a few days and 30-50% of patients suffer from chronic oxaliplatin-induced peripheral neuropathy (OIPN). 2 4 OIPN grade and symptom duration can be variable between studies. 2 However, although these symptoms seem to decrease with time, OIPN can last for several years after the end of the chemotherapy. 2 5 The great majority of studies have demonstrated a link between a cumulative dose above 850 mg/m 2 oxaliplatin and the onset of neuropathy. 2 OIPN presents specific sensory disturbances, with cold and warm triggered pain and a decrease in vibratory perception in the hands and feet. 6 In the longer term, OIPN has a deleterious impact on cancer survivors, often being associated with sleep disturbance, depressive symptoms and impaired health-related quality of life (HRQOL). 7 8 Based on literature analysis, there are no pharmacological agents recommended for the prevention of OIPN and other CIPNs. Duloxetine is the only treatment that can be proposed for the treatment of CIPN, but with recommendations for moderation. 9 Considering that colorectal cancer survivors represent the third largest group of cancer survivors, 10 innovative strategies are needed to improve the prevention and/or treatment of OIPN. Among these innovative strategies, specific diets provide real opportunities for the management of neuropathy symptoms.
11
A polyamine-reduced diet (PRD) containing less than 10 mg/kg of polyamines can relieve pain hypersensitivity (inflammatory and neuropathic pain) in animals. 12 Polyamines ( putrescine, spermidine and spermine) are polycations ubiquitously distributed in eukaryotic cells and mainly originating from dietary intake. 13 Polyamines are known to be positive modulators of NR2B containing N-methyl-D-aspartate (NMDA) receptors which are involved in central sensitisation following peripheral nerve injury.
14 As such, polyamines may play a facilitating role in nociceptive neurotransmission and pain chronicisation. 12 One main hypothesis is that reducing polyamine intake may improve nociceptive symptoms by decreasing NMDA receptor activity. 12 The same PRD has recently been assessed with success in a rat model of oxaliplatin-induced acute nerve hyperexcitability. 15 A PRD initiated 7 days before the beginning of the experiments completely prevented acute cold hypersensitivity and mechanical allodynia induced by a single oxaliplatin injection in rats. 15 More interestingly, an increase of glutamate concentration in the spinal cord was found in neuropathic animals, which was completely suppressed in PRD-fed animals. 15 Finally, this PRD was well tolerated by animals with no significant adverse effect. 12 15 This PRD has already been assessed in oncology for its antiproliferative properties 16 and is well tolerated by patients. [17] [18] [19] In clinical practice, this PRD is composed of a diet with low polyamine containing foods available in canned form (Polydol, Nutrialys Medical Nutrition, Saint-Grégoire, France). 18 Consequently, these preliminary results in animals can be translated into a clinical trial to validate the preventive effect of a PRD on OIPN.
METHODS AND ANALYSIS Study design
The present study is a prospective, randomised, controlled, single-blind and monocentric, phase II/III trial that compares a PRD versus a diet with medium polyamine content to prevent OIPN.
Study objectives
The main objective is to demonstrate a decrease of the cold triggered pain threshold 2 weeks after the third cycle of chemotherapy in a group of patients receiving a PRD compared to a control group receiving a diet with medium polyamine content. Cold thermal sensitivity is a characteristic symptom of OIPN after the third cycle of chemotherapy. 6 The other objectives of the study are to demonstrate an improvement of: hot triggered pain thresholds, vibration detection threshold, neuropathy grades and neuropathic pain. Besides the reduction of neuropathy symptoms, the trial aims at demonstrating an improvement of anxiety and depressive disorders as well as HRQOL in the PRD group compared to the control group. All these objectives will be assessed during the period of diet control (PRD or diet with medium polyamine content) from day 7 until day 100, after the beginning of oxaliplatin-based chemotherapy and after the return to a normal diet, for all the patients from day 100 until day 154 (end of the study). Under these conditions, a potential persisting effect of the PRD will be monitored from day 100 to day 154.
Inclusion and exclusion criteria
Participants are patients expected to receive adjuvant, neo-adjuvant or palliative oxaliplatin-based chemotherapy. The cycle length of the chemotherapy must be 15 days (eg, FOLFOX). The expected duration of treatment must be at least of eight cycles (4 months; for details see box 1) .
No treatment contraindication is imposed by the study. The oncologist will have a free choice of prescription for the therapeutic management of patients.
Each patient can be withdrawn of the study according to the following reasons: chemotherapy modification without oxaliplatin, intolerance to Polydol, withdrawal of consent, significant medical event.
Nutritional interventions
Before the beginning of the chemotherapy cycles until day 100, each patient will receive a specific diet according to group randomisation, that is, a PRD or a diet with medium polyamine content. Whatever the diet received, the daily intake for each patient will be about 2000 kcal. At day 100, patients will stop the imposed diet (PRD or diet with medium polyamine content) and return to normal feeding. All patients have to report in a notebook their daily intakes and any adverse effects in order to assess compliance with the diet and its safety.
Polyamine-reduced diet
Depending on the chemotherapy course, the PRD will associate 2 to 4 cans/day of Polydol (Nutrialys Medical Nutrition, Saint-Grégoire, France; tables 1 and 2) and meals with low polyamine content 18 (examples of PRD are presented in the tables 3-5). Polydol is a nutritional drink containing all the requisite nutrients but with low polyamine content (357 nmol/L of polyamines and 300 kcal per can of Polydol, data from Nutrialys Medical Nutrition). The number of cans of Polydol per day is adjusted as a function of the time course of the chemotherapy in order to optimise the patient's compliance with the diet while maximising the depletion of polyamine at the time of oxaliplatin administration (figure 1). Before the first chemotherapy cycle, patients will take 4 cans/day of Polydol for 7 days and 3 cans/day after the first chemotherapy infusion. For the other chemotherapy cycles, patients will take 3 cans/day of Polydol, 2 days before and 2 days after the chemotherapy infusions. Finally, between each chemotherapy infusion, the patients will receive 2 cans/day of Polydol (figure 1).
According to the diets defined above, polyamine intake will be about 29, 39 and 50 µmol per day with 4, 3 and 2 cans/day of Polydol, respectively (data from Nutrialys Medical Nutrition).
Diet with medium polyamine content
The diet with medium polyamine content will associate 1 can of Polydol with a defined diet of medium polyamine content 18 (examples of diets with medium polyamine content are presented in table 6). This diet will be maintained throughout the study until day 100. A placebo of Polydol with normal polyamine content is not technically feasible, but the association of only 1 can of Polydol with medium polyamine content is expected to provide an amount of polyamines equivalent to a normal diet (425 µmol/day; data from Nutrialys Medical Nutrition).
Study end points
The primary end point is the cold pain threshold (°C) in the hands (right and left thenar eminence) 42 days after the beginning of the oxaliplatin-based chemotherapy (2 weeks after the third cycle of chemotherapy; MEDOC TSA-II, Abioz Technologies, Ramat Yishai, Israel). The main secondary end points are presented hereafter and will be assessed throughout the study from 7 days before the beginning of chemotherapy until the The amount of polyamines is estimated at 29 µmol/day. PRD, polyamine-reduced diet. 23 
Methodology and study design
The trial is performed at a single site. All the patients are recruited, treated and followed-up at the digestive surgery and oncology unit of the University Hospital of Clermont-Ferrand, France.
After controlling the inclusion and exclusion criteria, the NEUROXAPOL trial will be proposed by oncologists (CP and DP) to patients suffering from digestive tract cancer and requiring oxaliplatin-based chemotherapy, admitted in the oncology unit of the University Hospital of Clermont-Ferrand. The patients will be informed of the trial protocol and, on acceptance, will be randomised in the PRD group or in the diet with medium polyamine content group. Randomisation is performed using a dedicated centralised telephone system, accessible round the clock, and using a computer-generated allocation sequence. The randomisation sequence is generated by biostatistician (BP) using random blocks and stratified according to the presence or not of a tumour. Tumours can release polyamines in the blood stream and may influence outcomes. 24 The NEUROXAPOL trial is a single-blind protocol because it is impossible to use a placebo for the PRD and the Polydol cans. Under these conditions, the investigator and the clinical research technician will know the type of diet taken by the patients. However, the primary end point (cold pain threshold in hands) is an independent measure performed by the investigator and the clinical research technician, using a validated medical device (MEDOC TSA-II, Abioz Technologies, Ramat Yishai, Israel).
The follow-up visits of patients will be very similar to the standard therapeutic practice in the oncology unit, so the number of missing data should be limited. Moreover, the compliance of patients to the proposed diet will be registered in a patient notebook throughout the study and considered in the statistical analysis.
Statistical considerations
Estimation sample size According to our previous works and literature, 6 we calculated that a sample size of n=35 patients by randomised group would provide 90% statistical power to detect an absolute difference of 5°C in the primary outcome 2 weeks after the third cycle of oxaliplatinbased chemotherapy (baseline of cold pain threshold in the hands at 8°C and standard-deviation equal to 6.3°C), for a two-sided α level of 0.05. Finally, a total of 80 patients will be considered. An interim analysis is planned after enrolment of the first 36 patients using the Lan and DeMets method (East software, Cytel Inc, Cambridge, Massachusetts, USA).
Statistical analysis
Statistical analysis will be conducted on intention to treat (ITT) using Stata software, V.13 (StataCorp, College Station, Texas, USA). A two-sided p value of less than 0.05 will be considered to indicate statistical significance (except interim analysis). Baseline characteristics will be presented for each randomised group as the mean±SD or the median (IQR) according to the statistical distribution for continuous data, and as the number of patients and associated percentages for Figure 1 Administration scheme of polyamine-reduced diet according to the time course of chemotherapy cycle.
Table 6
Examples of diet with medium polyamine content with one can of Polydol per day 25 the primary analysis will be completed by an ANCOVA considering the cold pain threshold in the hands 2 weeks after the third cycle of oxaliplatin-based chemotherapy as a dependent variable, and the group and the baseline value of cold pain threshold in the hands as independent parameters. Regarding the analysis of repeated measures, a random-effect model (linear or generalied linear) will be considered, as usually proposed, to study the fixed effects group, time points and interaction 'group x time', taking into account between and within subject variability. According to clinical relevance, the multivariate analysis will consider oxaliplatin doses (single and cumulative) as adjustment covariate for each outcome assessed. To assess possible problems caused by missing data, the estimation methods developed by Verbeke and Molenberghs will be proposed. 26 Dissemination Approval Any substantial change in the protocol and any change in the informed consent form will be presented to the independent medical ethics committee. The independent medical ethics committee and the competent French authority will be informed of the end of the study. In accordance with the independent medical ethics committee (Comité de Protection des Personnes Sud Est 1, Saint Etienne, France), no safety and data monitoring committee has been set up considering the low risk of the nutritional intervention.
The study is currently registered on the clinical trials website under the following number: NCT01775449. The protocol is currently in the V.8 since 14/1/2014.
Patient informed consent
According to the French law on clinical trials, written informed consent must be obtained from patients prior to participation in the study. Patients will voluntarily confirm their willingness to participate in the study, after having been informed (in writing and verbally) by oncologists of all aspects of the study that are relevant to their decision to participate. They will be informed about requirements concerning data protection and have to agree to direct access to their individual data. The patients will be informed that they are free to withdraw from the study at any time at their own discretion without necessarily giving reasons.
Data collection and quality management A clinical research technician (BG) is dedicated to the data entry, coding, security and storage. Each included patient and study data are anonymisated. Study data are collected and managed using REDCap electronic data capture tools hosted at University Hospital of Clermont-Ferrand. 27 REDCap (Research Electronic Data Capture) is a secure, web-based application designed to support data capture for research studies, providing: (1) an intuitive interface for validated data entry; (2) audit trails for tracking data manipulation and export procedures; (3) automated export procedures for seamless data downloads to common statistical packages; and (4) procedures for importing data from external sources.
A clinical research assistant will be commissioned by the sponsor (University Hospital of Clermont-Ferrand) in order to monitor the progress of the study in accordance with the Standard Operating Procedures implemented in the University Hospital of Clermont-Ferrand, in accordance with the Good Clinical Practice and the current French laws.
Access to data and dissemination of results
The data set will be propriety of the sponsor (CHU Clermont-Ferrand). However, the principal investigator (DP) and the project manager (DB) will have a full access to the final data set.
The results will be disseminated in a peer-reviewed journal, presented at international congresses and completed online on ClinicalTrials.gov.
DISCUSSION
This translational research project aims to demonstrate the preventive effect of a PRD on OIPN on both the acute and chronic symptoms of thermal hyperaesthesia, notably cold hyperaesthesia. These cold-induced symptoms are very good biomarkers of OIPN and their precocity are predictive of a strong chronic neuropathy after the repetition of chemotherapy cycles. 6 Therefore, the thermal threshold of cold triggered pain should be a reliable, sensitive and quantitative end point for assessing OIPN.
OIPN remains a problematic adverse drug reaction in digestive oncology, because up to 50% of patients can be affected and to this day, no preventive or curative strategy has proven indisputably effective. 9 Neuropathy symptoms can last for months and even years after the end of chemotherapy (25 months, 28 48 months 29 and 8 years 5 ) and the lack of support induces depression, sleep disorders 7 and a decrease of HRQoL. 7 8 Finally, CIPN has a strong economic and social impact, as patients with CIPN generate significant excess healthcare costs and resource use amounting to $17 344 per patient per year. 30 Innovative therapeutic strategies are now more than necessary to control both OIPN and CIPN in oncology.
